Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
All publications mentioned herein are cited for the purpose of familiarizing the reader with the background of the invention. Nothing herein is to be construed as an admission that these references are prior art in relation to the inventions described herein.
Although Type 2 Diabetes
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is the National Stage of Application No. PCT/US07/64974 filed Mar. 27, 2007, which claims benefit under 35 U.S.C. .sctn.119(e) of U.S. Provisional Application No. 60/787,104, filed Mar. 29, 2006, the contents of which are incorporated herein by reference in their entirety.
The
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to novel imidazole derivatives that are used as aldosterone synthase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase (CYP11B2) and/or 11-beta-hydroxylase (CYP11B1).
The present invention provides a compound of formula
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: MIRG.sub.--022.sub.--01WO_SeqList_ST25.txt, date recorded:
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase.
The present invention provides a compound of formula (I)
##STR00002## wherein
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase.
The present invention provides a compound of formula (I)
##STR00002## wherein
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase.
The present invention provides a compound of formula (I)
##STR00002## wherein
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
The use of a combination of non .beta.-oxidizable fatty acid entities and a protein material has shown surprising synergistic effects. The present invention concerns a composition prepared from a combination of compounds comprising non .beta.-oxidizable fatty acid entities and a
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to pyridoxine phosphonate analogues, to pyridoxine malonate analogues, to their preparation, to pharmaceutical compositions thereof, and to treatments for cardiovascular and related diseases, for example, hypertrophy, hypertension, congestive heart
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
INCORPORATION BY REFERENCE
The sequence listing ("Sequence Listing") submitted in ASCII text filed in connection with this application, 219KB, created May 21, 2014, and the Substitute Sequence Listing submitted in ASCII text created Nov. 9, 2015, 231KB, are incorporated herein by reference.
FIELD OF
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
INCORPORATION BY REFERENCE
The sequence listing ("Sequence Listing") submitted in ASCII text filed in connection with this application, created Nov. 9, 2015, 231 KB, is incorporated herein by reference.
FIELD OF INVENTION
The present invention is directed to compounds, their synthesis, and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
INCORPORATION BY REFERENCE
The sequence listing ("Sequence Listing") submitted in ASCII text filed in connection with this application, created Nov. 9, 2015, 231 KB, is incorporated herein by reference.
FIELD OF INVENTION
The present invention is directed to compounds, their synthesis, and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention focuses on definition of pharmaceutical compositions and proposed method for the treatment of metabolic syndrome, diabetes mellitus and aging. Compounds and compositions of natural origin are disclosed in the description. More particularly, this invention
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse. * Kogu teave põhineb avaldatud teaduslikel uuringutel